SEC Form 4 · accession 0001104659-18-019046
Amphastar Pharmaceuticals, Inc. · AMPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason B. Shandell
Officer — President and General Counsel · Director
Period of report
Mar 16, 2018
Accepted (ET)
Mar 20, 2018 · 8:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001297184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 16, 2018 | F | 5,495 | $19.91 | D | 251,372 | D | |
| Common StockF1 | Mar 17, 2018 | F | 6,486 | $19.91 | D | 244,886 | D | |
| Common StockF3 | Mar 19, 2018 | S | 11,707 | $19.3702 | D | 233,179 | D | |
| Common StockF4 | Mar 20, 2018 | S | 8,293 | $19.519 | D | 224,886 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.
- F2The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2017.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.05 to $19.62 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.39 to $19.91, inclusive.